Psoriasis drug achieves phase III endpoint

Article

Efalizumab (Raptiva), an investigational therapy for moderate-to-severe psoriasis, achieved its primary efficacy endpoint in a randomized phase III study.

Related Videos
© 2023 MJH Life Sciences

All rights reserved.